Do analysts prefer ATXI or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ATXI or CDT?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avenue Therapeutics N/A N/A -$10.38M -$0.85 N/A CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A

Is ATXI or CDT more profitable?

CDT Equity's return on equity of -72.25% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% CDT Equity N/A -72.25% -55.44%

Do analysts rate ITRM or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ITRM or CDT more profitable?

Iterum Therapeutics' return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% CDT Equity N/A -72.25% -55.44%

Do analysts recommend CDT or CANF?

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 1,831.52%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is CDT or CANF more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -72.25% -55.44% Can-Fite BioPharma N/A N/A N/A

Does the media favor CDT or CANF?

In the previous week, CDT Equity had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 4 mentions for CDT Equity and 3 mentions for Can-Fite BioPharma. CDT Equity's average media sentiment score of 0.46 beat Can-Fite BioPharma's score of -0.26 indicating that CDT Equity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CDT Equity 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend CDT or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, CDT or BPTH?

Bio-Path is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$3.35 thousand N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is CDT or BPTH more profitable?

CDT Equity's return on equity of -72.25% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -72.25% -55.44% Bio-Path N/A -2,842.40% -337.48%

Do analysts rate ASLN or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or CDT more profitable?

CDT Equity's return on equity of -72.25% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% CDT Equity N/A -72.25% -55.44%

CDT Equity (CDT) Competitors

$0.21 -0.01 (-4.57%)

As of 10:32 AM Eastern

Compare

CDT vs. ATXI, ITRM, CANF, BPTH, and ASLN

Should you buy CDT Equity stock or one of its competitors? CDT Equity's main competitors and comparable companies include Avenue Therapeutics (ATXI), Iterum Therapeutics (ITRM), Can-Fite BioPharma (CANF), Bio-Path (BPTH), and ASLAN Pharmaceuticals (ASLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CDT Equity compare to Avenue Therapeutics?

Avenue Therapeutics (NASDAQ:ATXI) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

In the previous week, CDT Equity had 4 more articles in the media than Avenue Therapeutics. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Avenue Therapeutics. CDT Equity's average media sentiment score of 0.46 beat Avenue Therapeutics' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
CDT Equity	Neutral

Avenue Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

CDT Equity's return on equity of -72.25% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
CDT Equity	N/A	-72.25%	-55.44%

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 7.3% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CDT Equity beats Avenue Therapeutics on 6 of the 11 factors compared between the two stocks.

How does CDT Equity compare to Iterum Therapeutics?

Iterum Therapeutics (NASDAQ:ITRM) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Iterum Therapeutics' return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
CDT Equity	N/A	-72.25%	-55.44%

Iterum Therapeutics has higher revenue and earnings than CDT Equity. Iterum Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 7.3% of CDT Equity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, CDT Equity had 4 more articles in the media than Iterum Therapeutics. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Iterum Therapeutics. CDT Equity's average media sentiment score of 0.46 beat Iterum Therapeutics' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
CDT Equity	Neutral

Summary

Iterum Therapeutics beats CDT Equity on 7 of the 12 factors compared between the two stocks.

How does CDT Equity compare to Can-Fite BioPharma?

CDT Equity (NASDAQ:CDT) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Can-Fite BioPharma has higher revenue and earnings than CDT Equity. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A
Can-Fite BioPharma	$405K	3.68	-$7.63M	-$22.80	N/A

Can-Fite BioPharma's return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-72.25%	-55.44%
Can-Fite BioPharma	N/A	N/A	N/A

CDT Equity has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, CDT Equity had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 4 mentions for CDT Equity and 3 mentions for Can-Fite BioPharma. CDT Equity's average media sentiment score of 0.46 beat Can-Fite BioPharma's score of -0.26 indicating that CDT Equity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CDT Equity	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Can-Fite BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 1,831.52%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 7.3% of CDT Equity shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Can-Fite BioPharma beats CDT Equity on 9 of the 14 factors compared between the two stocks.

How does CDT Equity compare to Bio-Path?

CDT Equity (NASDAQ:CDT) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Bio-Path is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

CDT Equity has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market.

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 7.3% of CDT Equity shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CDT Equity's return on equity of -72.25% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-72.25%	-55.44%
Bio-Path	N/A	-2,842.40%	-337.48%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, CDT Equity had 4 more articles in the media than Bio-Path. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Bio-Path. CDT Equity's average media sentiment score of 0.46 beat Bio-Path's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Neutral
Bio-Path	Neutral

Summary

CDT Equity beats Bio-Path on 8 of the 11 factors compared between the two stocks.

How does CDT Equity compare to ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

CDT Equity has lower revenue, but higher earnings than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
CDT Equity	N/A	N/A	-$39.22M	-$3.35 thousand	N/A

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 7.3% of CDT Equity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

CDT Equity's return on equity of -72.25% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
CDT Equity	N/A	-72.25%	-55.44%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, CDT Equity had 4 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for ASLAN Pharmaceuticals. CDT Equity's average media sentiment score of 0.46 beat ASLAN Pharmaceuticals' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
CDT Equity	Neutral

Summary

CDT Equity beats ASLAN Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Get CDT Equity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDT vs. The Competition

Export

Metric	CDT Equity	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$164K	$12.42B	$7.15B	$14.21B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	0.00	794.66	273.46	25.34
Price / Sales	N/A	763.71	670.93	98.74
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	0.00	10.44	10.43	6.20
Net Income	-$39.22M	$2.83B	$3.48B	$357.95M
7 Day Performance	-66.12%	-2.70%	-1.90%	-1.21%
1 Month Performance	-92.84%	1.15%	-0.14%	-3.22%
1 Year Performance	-99.98%	3.82%	19.12%	6.27%

CDT Equity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDT CDT Equity	0.1828 of 5 stars	$0.21 -4.6%	N/A	-100.0%	$164K	N/A	N/A	3	Short Interest Increase Gap Down High Trading Volume
ATXI Avenue Therapeutics	N/A	$0.54 -0.8%	N/A	-16.9%	$1.78M	N/A	0.03	4
ITRM Iterum Therapeutics	0.0231 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
CANF Can-Fite BioPharma	1.9918 of 5 stars	$2.29 +2.7%	$44.00 +1,821.4%	-82.7%	$1.50M	$405K	N/A	8
BPTH Bio-Path	N/A	$0.03 flat	N/A	-99.8%	$1.39M	N/A	N/A	10	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDT) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CDT Equity (CDT) Competitors

CDT vs. ATXI, ITRM, CANF, BPTH, and ASLN

How does CDT Equity compare to Avenue Therapeutics?

Summary

How does CDT Equity compare to Iterum Therapeutics?

Summary

How does CDT Equity compare to Can-Fite BioPharma?

Summary

How does CDT Equity compare to Bio-Path?

Summary

How does CDT Equity compare to ASLAN Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CDT Equity (CDT) Competitors

CDT vs. ATXI, ITRM, CANF, BPTH, and ASLN

How does CDT Equity compare to Avenue Therapeutics?

Which has preferable earnings & valuation, ATXI or CDT?

Does the media favor ATXI or CDT?

Which has more risk & volatility, ATXI or CDT?

Is ATXI or CDT more profitable?

Do insiders & institutionals believe in ATXI or CDT?

Do analysts prefer ATXI or CDT?

Summary

How does CDT Equity compare to Iterum Therapeutics?

Is ITRM or CDT more profitable?

Which has better earnings and valuation, ITRM or CDT?

Which has more volatility & risk, ITRM or CDT?

Do analysts rate ITRM or CDT?

Do institutionals and insiders have more ownership in ITRM or CDT?

Does the media prefer ITRM or CDT?

Summary

How does CDT Equity compare to Can-Fite BioPharma?

Which has higher earnings and valuation, CDT or CANF?

Is CDT or CANF more profitable?

Which has more risk and volatility, CDT or CANF?

Does the media favor CDT or CANF?

Do analysts recommend CDT or CANF?

Do insiders & institutionals have more ownership in CDT or CANF?

Summary

How does CDT Equity compare to Bio-Path?

Which has stronger earnings and valuation, CDT or BPTH?

Which has more volatility & risk, CDT or BPTH?

Do insiders and institutionals hold more shares of CDT or BPTH?

Is CDT or BPTH more profitable?

Do analysts recommend CDT or BPTH?

Does the media favor CDT or BPTH?

Summary

How does CDT Equity compare to ASLAN Pharmaceuticals?

Which has preferable valuation and earnings, ASLN or CDT?

Do institutionals and insiders believe in ASLN or CDT?

Which has more volatility & risk, ASLN or CDT?

Is ASLN or CDT more profitable?

Do analysts rate ASLN or CDT?

Does the media refer more to ASLN or CDT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools